EVOLVA BIOTECH A/S - CVR: 25532538

2020, DKK

16.07.2021

Bruttoresultat

-116'

Primær drift

-116'

Årets resultat

-197'

Aktiver

6.486'

Kortfristede aktiver

6.486'

Egenkapital

6.379'

Afkastningsgrad

-2 %

Soliditetsgrad

98 %

Likviditetsgrad

+500%

Resultat

16.07.2021

Årsrapport	2020 16.07.2021	2019 21.09.2020	2018 22.07.2019	2017 29.05.2018	2016 02.06.2017	2015 13.05.2016
Nettoomsætning				69.884.999	59.907.653	47.695.083
Bruttoresultat	-116.208	638.876	2.917.430	0	0	0
Resultat af primær drift	-116.432	-199.698	109.917	187.419	182.223	0
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0
Finansielle indtægter	36.772	74.938	177.526	162.638	221.913	72.131
Finansieringsomkostninger	-117.146	-62.255	-46.057	-1.074.596	-1.023.668	-1.134.101
Andre finansielle omkostninger	0	0	0	0	0	0
Resultat før skat	-196.806	-187.015	241.386	-724.539	-619.532	0
Resultat	-196.806	-187.015	241.386	-724.539	-619.532	-1.051.709
Forslag til udbytte	0	0	0	0	0	0

Aktiver

16.07.2021

Årsrapport	2020 16.07.2021	2019 21.09.2020	2018 22.07.2019	2017 29.05.2018	2016 02.06.2017	2015 13.05.2016
Kortfristede varebeholdninger	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	6.385.685	5.387.744	7.953.307	13.655.752	1.637.050	1.859.975
Likvider	100.171	1.189.922	97.608	3.653.911	5.700.470	13.314.680
Kortfristede aktiver	6.485.856	6.577.666	8.050.915	17.309.663	7.337.520	15.174.655
Immaterielle aktiver og goodwill	0	0	0	0	0	0
Finansielle anlægsaktiver	0	0	6.000	0	6.035.481	5.984.744
Materielle aktiver	0	0	0	3.739.321	18.190.542	20.978.756
Langfristede aktiver	0	0	6.000	3.739.321	24.226.023	26.963.500
Aktiver	6.485.856	6.577.666	8.056.915	21.048.984	31.563.543	42.138.155

Aktiver

16.07.2021

Passiver

16.07.2021

Årsrapport	2020 16.07.2021	2019 21.09.2020	2018 22.07.2019	2017 29.05.2018	2016 02.06.2017	2015 13.05.2016
Forslag til udbytte	0	0	0	0	0	0
Egenkapital	6.378.584	6.575.390	6.762.405	6.521.019	7.245.558	7.865.091
Hensatte forpligtelser	0	0	0	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0
Anden langfristet gæld	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	105.000	0	82.652	1.727.674	1.688.529	3.094.376
Kortfristede forpligtelser	107.272	2.276	1.294.510	14.527.965	9.250.590	9.565.851
Gældsforpligtelser	107.272	2.276	1.294.510	14.527.965	24.317.985	34.273.064
Forpligtelser	107.272	2.276	1.294.510	14.527.965	24.317.985	34.273.064
Passiver	6.485.856	6.577.666	8.056.915	21.048.984	31.563.543	42.138.155

Passiver

16.07.2021

Nøgletal

16.07.2021

Årsrapport	2020 16.07.2021	2019 21.09.2020	2018 22.07.2019	2017 29.05.2018	2016 02.06.2017	2015 13.05.2016
Afkastningsgrad	-1,8 %	-3,0 %	1,4 %	0,9 %	0,6 %	Na.
Dækningsgrad	Na.	Na.	Na.	Na.	Na.	Na.
Resultatgrad	Na.	Na.	Na.	-1,0 %	-1,0 %	-2,2 %
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	-3,1 %	-2,8 %	3,6 %	-11,1 %	-8,6 %	-13,4 %
Payout-ratio	Na.	Na.	Na.	Na.	Na.	Na.
Gældsdæknings-nøgletal	-99,4 %	-320,8 %	238,7 %	17,4 %	17,8 %	Na.
Soliditestgrad	98,3 %	100,0 %	83,9 %	31,0 %	23,0 %	18,7 %
Likviditetsgrad	6.046,2 %	289.001,1 %	621,9 %	119,1 %	79,3 %	158,6 %

Resultat

16.07.2021

Gæld

16.07.2021

Årsrapport

16.07.2021

Nyeste:01.01.2020- 31.12.2020(offentliggjort: 16.07.2021)

Information om virksomhedens regnskabsklasse:The annual report of Evolva Biotech A/S under frivillig likvidation for 2020 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities with the necessary adjustments due to the Company currently undergoing liquidation. Further reference is made to note 2.

Beretning

16.07.2021

Dato for ledelsens godkendelse af årsrapporten:2021-07-15

Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Going concern As of 31 December 2020, the Company completed the transfer of all its activities to the Parent Company, Evolva SA, as part of the group-wide consolidation of the research and development activities in Reinach, Switzerland. As a consequence of the transfer of activities, it is Management's intention is to liquidate the Company in the nearest future. Since the Company is dormant in 2020, COVID-19 did not have any impact on the Company's operations.

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, I have discussed and approved the annual report of Evolva Biotech A/S under frivillig likvidation for the financial year 1 January - 31 December 2020.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:The Company's purpose is to carry on research and development, manufacturing and sales of ingredients and processes related to food, nutrition and personal care and to provide services to companies in Denmark and abroad as well as other related activities. On 30 August 2017, Evolva Holding AG announced to the public that the Evolva Group would undertake a major site consolidation of its research and development activities in the remaining months of 2017. As a result of this consolidation, all R&D activities in Evolva Biotech A/S have either been terminated or transfered to Evolva SA in Reinach Switzerland as of 31 December 2020.